The novel expanded porphyrin, motexafin gadolinium, combined with [ 90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: Preclinical findings and results of a phase I trial

Clinical Cancer Research

Volumn 15, Issue 20, 2009, Pages 6462-6471

  Evens, Andrew M ^a   Spies, William G ^a   Helenowski, Irene B ^a   Patton, David ^a   Spies, Stewart ^a   Jovanovic, Borko D ^a   Miyata, Sarah ^a   Hamilton, Elizabeth ^a   Variakojis, Daina ^a   Chen, Jun ^b   Naumovski, Louie ^b   Rosen, Steven T ^a   Winter, Jane N ^a   Miller, Richard A ^b   Gordon, Leo I ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b PHARMACYCLICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GADOLINIUM TEXAPHYRIN; IBRITUMOMAB TIUXETAN; PORPHYRIN; PREDNISONE; PROCHLORPERAZINE MALEATE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CELL DEATH; CHILL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CYTOPENIA; CYTOTOXICITY; DIARRHEA; DRUG DOSE ESCALATION; DRUG POTENTIATION; EDEMA; FATIGUE; FEMALE; FOLLICULAR LYMPHOMA; HEADACHE; HISTOLOGY; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; INSOMNIA; LARGE CELL LYMPHOMA; LYMPHOMA CELL; MALE; MANTLE CELL LYMPHOMA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PAIN; PRIORITY JOURNAL; PRURITUS; RADIOIMMUNOTHERAPY; REMISSION; RIGOR; SIDE EFFECT; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; METALLOPORPHYRINS; MIDDLE AGED; PORPHYRINS; RADIATION-SENSITIZING AGENTS; RADIOIMMUNOTHERAPY; RECURRENCE; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 70350219110     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0905     Document Type: Article

References (42)

1. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. JClin Oncol 2000;18:1316-1323 (Pubitemid 30159851)
2. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002;99:4336-4342
3. Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004;103:4429-4431 (Pubitemid 38745967)
4. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005;23:7565-7573
5. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:3262-3269 (Pubitemid 34831524)
6. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-2463 (Pubitemid 34525730)
7. Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. JClin Oncol 2005;23:712-719 (Pubitemid 46224170)
8. Evens AM, Lecane P, Magda D, et al. Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells. Blood 2005;105: 1265-1273 (Pubitemid 40170902)
9. Hashemy SI, Ungerstedt JS, Zahedi Avval F, Holmgren A. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J Biol Chem 2006;281:10691-10697 (Pubitemid 43855490)
10. Magda D, Miller RA. Motexafin gadolinium: a novel redox active drug for cancer therapy. Semin Cancer Biol 2006;16:466-476 (Pubitemid 44780135)
11. Miller RA, Woodburn KW, Fan Q, et al. Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin. Clin Cancer Res 2001;7:3215-3221 (Pubitemid 32963846)
12. Woodburn KW. Intracellular localization of the radiation enhancer motexafin gadolinium using interferometric Fourier fluorescence microscopy. J Pharmacol Exp Ther 2001;297:888-894
13. Magda D, Gerasimchuk N, Lecane P, Miller RA, Biaglow JE, Sessler JL. Motexafin gadolinium reacts with ascorbate to produce reactive oxygen species. Chem Commun (Camb) 2002: 2730-2731 (Pubitemid 35351988)
14. Magda D, Lepp C, Gerasimchuk N, et al. Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int J Radiat Oncol Biol Phys 2001;51:1025-1036 (Pubitemid 33026434)
15. Mehta MP, Shapiro WR, Phan SC, et al. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys 2008.
16. Mehta MP, Shapiro WR, Glantz MJ, et al. Leadin phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 2002;20: 3445-3453
17. Carde P, Timmerman R, Mehta MP, et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 2001;19:2074-2083 (Pubitemid 32702553)
18. Xu S, Zakian K, Thaler H, et al. Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity. Int J Radiat Oncol Biol Phys 2001;49:1381-1390 (Pubitemid 32294318)
19. Mehta MP, Rodrigus P, Terhaard CH, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003;21:2529-2536 (Pubitemid 46606335)
20. Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004; 22:157-165 (Pubitemid 41095128)
21. Miller RA, Woodburn K, Fan Q, Renschler MF, Sessler JL, Koutcher JA. In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int J Radiat Oncol Biol Phys 1999;45: 981-989
22. Gordon LI, Witzig TE, Wiseman GA, et al. Yttrium 90 ibritumomabtiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Semin Oncol 2002;29:87-92. (Pubitemid 34171800)
23. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
24. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) Bcell non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3793-3803
25. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. JASA 1958;53: 457-481
27. Cox DR. Regression models and life tables. JR Stat Soc (B) 1972;34:187-220.
28. Lecane PS, Karaman MW, Sirisawad M, et al. Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res 2005;65:11676-11688 (Pubitemid 41821728)
29. Chen J, Ramos J, Sirisawad M, et al. Motexafin gadolinium induces mitochondrially-mediated caspase-dependent apoptosis. Apoptosis 2005; 10:1131-1142 (Pubitemid 41285588)
30. Ramos J, Sirisawad M, Miller R, Naumovski L. Motexafin gadolinium modulates levels of phosphorylated Akt and synergizes with inhibitors of Akt phosphorylation. Mol Cancer Ther 2006;5: 1176-1182 (Pubitemid 43881309)
31. Gartenhaus RB, Prachand SN, Paniaqua M, Li Y, Gordon LI. Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. Clin Cancer Res 2002;8:566-572 (Pubitemid 34193978)
32. Bellosillo B, Villamor N, Lopez-Guillermo A, et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders ismediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 2001;98:2771-2777
33. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006;107:257-264 (Pubitemid 43053550)
34. Shanafelt TD, Lee YK, Bone ND, et al. Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. Blood 2005;105:2099-2106
35. Miller CP, Ban K, Dujka ME, et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007;110:267-277 (Pubitemid 47026844)
36. Viala J, Vanel D, Meingan P, Lartigau E, Carde P, Renschler M. Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases. Radiology 1999;212:755-759 (Pubitemid 29410979)
37. Rosenthal DI, Nurenberg P, Becerra CR, et al. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 1999;5:739-745 (Pubitemid 29180823)
38. Morschhauser F, Illidge T, Huglo D, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 2007;110:54-58 (Pubitemid 47026818)
39. Gordon LI. Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Oncol 2003;30:23-28 (Pubitemid 38049934)
40. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003;21:1263-1270 (Pubitemid 46606402)
41. Pervan MCJ, Matso D, Said JW, McBride WH, de Vos S. Active Combination therapy of bortezomib (Velcade) and ibritumomab tiuxetan (Zevalin) in an in vivo diffuse large b-cell lymphoma model. Blood 2005;106:2406a.
42. Witzig TEWG, Weiner G, Ansell SM, et al. A phase I trial of CpG-7909, rituximab immunotherapy, and Y90 Zevalin radioimmunotherapy for patients (pts) with previously treated CD20+ non-Hodgkin lymphoma. Blood 2007; 110:124a.